Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
featured
LUX-Lung IO: A phase II, open label, non-randomised study of afatinib in combination with pembrolizumab in patients with locally advanced or metastatic squamous cell carcinoma of the lung

LUX-Lung IO: A phase II, open label, non-randomised study of afatinib in combination with pembrolizumab in patients with locally advanced or metastatic squamous cell carcinoma of the lung

platinum-based chemotherapy
squamous cell carcinoma
chemotherapy regimen
chemoradiotherapy
lung carcinoma
  • 538 views
  • 24 Nov, 2020
  • 1 location
featured
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.

solid tumor
malignant solid tumor
advanced solid tumor
  • 405 views
  • 16 Dec, 2020
  • 63 locations
Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer

This is a single arm open-label multi-center phase II study, investigating disease control rate after 18 weeks of treatment with afatinib/cetuximab combination therapy in patients with advanced

platelet count
epidermal growth factor receptor
systemic therapy
growth factor
secondary malignant neoplasm of liver
  • 20 views
  • 16 Jun, 2019
  • 2 locations
An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR a HER2 or a HER3 Mutation

Objective(s):To investigate the efficacy and safety of afatinib in EGFR, HER 2 and HER3 mutated cancers, regardless of cancer type, excluding EGFR mutated non-small cell lung cancer.

  • 0 views
  • 22 Jan, 2021
  • 5 locations
Afatinib Paclitaxel 2nd Line Advanced Gastric Cancer

For the gastric cancer, paclitaxel is recommended as salvage standard treatment. Afatinib is a novel, potent, small ErbB family blocker that covalently binds and irreversibly blocks signaling

platelet count
trastuzumab
cancer chemotherapy
adjuvant chemotherapy
neutrophil count
  • 7 views
  • 23 Jan, 2021
  • 1 location
Afatinib in Advanced Refractory Urothelial Cancer

This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line

bladder carcinoma
metastatic urothelial carcinoma
transitional cell carcinoma
chemotherapy regimen
human epidermal growth factor receptor 2
  • 29 views
  • 25 Jan, 2021
  • 4 locations
Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity

To assess if targeting activating EGFR and HER2 mutations in Non-Small Cell Lung Cancer (NSCLC) is more effective when these mutations are truncal dominant mutations (50%), as opposed to non-dominant (5 to <50%) or low frequency mutations (<5%). This trial will be available to patients registered to the TRACERx study …

neutrophil count
secondary malignant neoplasm of liver
erbb2
lung carcinoma
measurable disease
  • 31 views
  • 25 Jan, 2021
  • 7 locations
Afatinib With CT and RT for EGFR-Mutant NSCLC

tyrosine kinase inhibitor (TKI) can help increase the response to treatment. Afatinib is a tyrosine kinase inhibitor. It has been studied in a previous research study in participants with more

experimental drug
epidermal growth factor receptor
epidermal growth factor
lung carcinoma
tyrosine
  • 0 views
  • 24 Jan, 2021
Effect of Zanthoxylum Nitidum Tincture for Paronychia Caused by Afatinib

This is a randomized control trial evaluating the efficacy of zanthoxylum nitidum tincture on preventing progression of paronychia caused by afatinib from grade 1 to grade 2/3. Enrolled

  • 0 views
  • 24 Jan, 2021
  • 1 location
Neoadjuvant Afatinib Therapy for Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

approved afatinib for first-line treatment of patients with metastatic NSCLC who have sensitizing EGFR mutations.The treatment of stage III NSCLC remains a matter of debate. Current multimodality treatment

  • 0 views
  • 24 Jan, 2021
  • 1 location